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Editor’s key points
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† This study found no
significant differences in





† In patients with small
frontal tumours, there is
no need to alter propofol
dosage or its titration
according to BIS.
† The thresholds at which
the extent and type of
intracranial pathologies
affect BIS are largely
unknown.
Background. The influence of frontal brain tumours on bispectral index (BIS) measurements
and propofol requirements is unknown. The primary aim of our study was to determine
whether BIS values recorded at loss and return of consciousness (LOC and ROC, respectively)
differ between patients with unilateral frontal brain tumours and control patients.
Secondary goals were to compare propofol requirements for LOC and to determine whether
there were significant inter-hemispheric differences between BIS values in tumour and
control patients.
Methods.We enrolled 20 patients with a frontal brain tumour and 20 control patients. Bilateral
BIS measurements were done during induction of propofol anaesthesia, during recovery of
consciousness, and during a second induction of anaesthesia. The isolated-forearm test
was used to determine the moments of LOC1, ROC, and LOC2. Arterial blood samples were
obtained every 4 min for determination of measured propofol concentrations.
Results. The median BIS values recorded at LOC1, ROC, and LOC2 did not differ between the
groups. There were no significant inter-hemispheric differences in BIS in tumour and control
patients. The median [inter-quartile range (IQR)] total propofol doses at LOC1 were 82 (75–92)
and 78 (68–91) mg in tumour and control patients, respectively. The median (IQR)
measured plasma propofol concentrations at LOC1 were 12 (9–14) and 13 (11–15) mg ml21
in the tumour and control groups, respectively.
Conclusions. The presence of a frontal brain tumour did not affect ipsilateral BIS values, and so
need not influence the placement of unilateral BIS electrodes if BIS monitoring is used to
titrate propofol anaesthesia.
Keywords: brain tumour; depth of anaesthesia; monitoring, bispectral index; pharmacology,
propofol
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Many anaesthetists measure and record the bispectral index
(BIS) (Bispectral Index, Covidien, Boulder, CO, USA) during cra-
niotomy for excision of brain tumours, and use the BIS to guide
titration of the anaesthetic agents. However, there have been
few studies investigating the influence of brain tumours on
the reliability of the BIS as a measure of hypnosis. As far as
we know, no studies have specifically addressed the issue of
the influence of frontal brain tumours on the relationship
between the BIS and conscious state.
One study, involving 13 patients with small supra- and infra-
tentorial tumours, and 13 control patients, was designed to
evaluate the relationship between estimated effect-site con-
centrations and the BIS during loss of consciousness (LOC).1
For induction of anaesthesia, propofol was administered at a
rate of 2000 mg h21 in all patients, but achieved plasma con-
centrations were not measured. Although the authors found
significantly higher overall BIS values over time in tumour
patients during the induction, and higher BIS values for
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estimated effect-site concentrations.2.5mg ml21, there were
no statistically significant differences in BIS and propofol con-
centrations at LOC. Overall, the findings were inconclusive, dif-
ficult to interpret, and limited by the small sample size and by
the inclusion of patients with non-frontal brain tumours.
It isacommon perception amonganaesthetiststhatpatients
withbraintumoursaresensitivetothe effectsofcommonlyused
anaesthetic agents, such as propofol, and accordingly they ad-
minister cautious induction doses. This practice, recommended
in some textbooks,2 is chiefly supported by clinical experience,
expert opinion, and by one small study which did indeed show
evidence that propofol requirements are decreased in patients
with large supratentorial brain tumours.3 During neurosurgery,
propofol-based total i.v. anaesthesia is commonly practiced,
with the propofol often administered by target-controlled infu-
sion (TCI). If there are pharmacokinetic, pharmacodynamic, or
both differences among patients with tumours, then the
models which are used for TCI propofol may be inaccurate in
these patients.
Overall, it remains unclear whether anaesthetic dose-titration
according to the BIS is advisable in patients with cranial tumours,
and whether or not these patients are more susceptible to the
hypnotic effects of propofol. The primary aim of our prospective
observational study was to compare BIS values recorded at LOC
and ROC among patients with unilateral frontal brain tumours
and patients with no brain tumour. Secondarygoals were to de-
termine whether there were differences between BIS values
recorded on the ipsilateral and contralateral hemispheres in
tumour patients, and to compare propofol dose and measured




After institutional ethics committee approval (UMCG ethics
committee, number 2009058) and registration at ClinicalTrials.-
gov (NCT01060631), we obtained informed consent from 53 ASA
I–III patients older than 18 yr of age for inclusion in the study.
The study group comprised 24 patients with a known frontal
intracranial tumour proven by a recently obtained magnetic res-
onance imaging (MRI) image, who were undergoing an elective
tumour excision. Patients were prospectively assessed for the
presence of significant neurological deficits. Those with any sen-
sorimotor or cognitive deficits that may have interfered with
assessments of consciousness were not considered eligible for
the study. For MRI images, see Figure 1. The control group com-
prised 29 patients without intracranial pathology planned to
undergo an elective spinal neurosurgical operation. Exclusion cri-
teriafor bothgroupswereanyconditionsor treatmentsthat could
potentially interfere with respiratory or cardiovascular status
of the patient during the study. Complete group allocation is
reported in Figure 2.
The study was performed before any surgical intervention
in a quiet operating theatre, with the following personnel
present: one coordinating researcher, one anaesthetist re-
sponsible for the safety and anaesthetic care of the patient,
one anaesthetic nurse, and a second anaesthetist responsible
for blood sampling and other tasks.
On arrival in the operating theatre, an i.v. cannula was
inserted in the non-dominant hand or forearm. All patients
received an i.v. infusion of crystalloid solution, at a rate of
500 ml h21, to deliver the required drugs and fluids during
the study period. After the placement of routine cardiovascu-
lar and respiratory monitors, an intra-arterial catheter was
inserted under topical anaesthesia in the non-dominant radial
artery and connected to a pressure transducer. Bilateral BIS
electrodes were placed as recommended by the manufacturer
and bilateral BIS and bilateral frontal electro-encephalographic
activity was recorded using a Vista monitor (Covidien) with
seven electrodes. Heart rate, three-lead ECG, capnography,
and pulse oximetry and invasive arterial pressure were also
recorded continuously using a Philips IntelliVue MP50 (Philips,
Eindhoven, The Netherlands) monitor. Numerical and wave-
form data were recorded electronically using Rugloop II &
software (Demed, Temse, Belgium). The raw electroenceph-
alogram was digitized at a rate of 128 Hz and stored for
post hoc analysis.
The timeline of the study is shown in Figure 3. Anaesthesia
was induced with continuous i.v. infusion of propofol 2% at a
rate of 100 ml h21. During induction of anaesthesia, patients
were verbally prompted every 10 s to squeeze the dominant
hand. For the verbal commands, an electronic recording was
relayed to the patient by headphones using Microsoft Windows
Media Player at maximum volume. The coordinating researcher
remainedatthepatient’sdominantsideandcouldheartheaudi-
torycommands.Theobserver informedtheotherinvestigatorsof
LOC at the time of the second failure of the patient to respond
to the verbal command. The following were then performed as
soon as possible: the time of the loss of response was recorded
electronically (by free text entry in RUGLOOP) and on paper,
the estimated effect-site concentration at LOC1 was noted,
the first arterial blood sample was withdrawn and the time
of withdrawal of the sample recorded, the fixed rate propofol
infusion was stopped, and an effect-site TCI propofol infusion
was begun with the target concentration set to that noted
at LOC1.
To improve the quality of EEG signals and BIS registration,
rocuronium bromide (Fresenius-Kabi, France) was administered
and a laryngeal mask airway (LMA) was inserted in order to
maintainapatentairway.Tofacilitateregistrationofsubsequent
responses to commands, the isolated forearm technique was
applied. Thus, before administration of rocuronium, a padded
tourniquet was applied to the dominant upper arm and inflated
20% above the systolic arterial pressure.
At 15 min after LOC1, a noxious stimulus in the form of a 30 s
electrical tetanic stimulus (100 Hz, 60 mA) was applied to the
dominant forearm. At 20 min after LOC, the propofol TCI
target was set to zero (thereby stopping the infusion) and
patients were again verbally prompted every 10 s to squeeze
the dominant hand. The second subsequent purposeful re-
sponse to this prompt was noted as return of consciousness
(ROC), the time was noted, and the propofol infusion was
restarted at 100 ml h21 until the response ceased and the
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patient lost consciousness for the second time (LOC2). This sig-
nalled the end of the study and further preparation for surgical
procedure was commenced as planned.
Propofol infusions were administered by Orchestra DPS in-
fusion pumps (Fresenius-Kabi) controlled by the RUGLOOP II
software. In addition to controlling the infusion pumps,
Fig 1 MRI images of tumour patients.
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RUGLOOP calculated and recorded plasma and effect-site
concentrations using the Schnider model4 during fixed rate
propofol administration, and calculated, implemented, and
recorded the required propofol infusion rates during TCI
administration. RUGLOOP also retrieved and electronically
recorded all measured physiological parameters, including
BIS values and unprocessed EEG signals, during the study.
Because of the fact that sympathomimetic agents may in-
fluence the BIS,5 administration of vasopressors was not per-
mitted. However, if the physician responsible for the clinical
care of the patient felt that such an intervention was necessary
to maintain the safety of the patient, then in keeping with GCP,
such therapy was administered, but the data of the patient
were excluded from further analysis, and a replacement
patient was eventually enrolled. The latter was also applied
to patients in whom there were no clear responses to
command, despite otherclear signs of consciousness. Replace-
ment was approved by the ethical committee.
Arterial blood samples (10 ml) were drawn every 4 min
throughout the study, starting at the moment of LOC1, with
Assessed  for  eligibility
Tumour patients Control patients
Declined to participate (n=3)
Granted informed
Did not participate in the study
because of staffing issue (n=1)
Did not participate in the study
because of staffing issue (n=1), or
cardiac morbidity (n=1)
Granted informed





Participated in the study
Excluded from analysis because of
protocol violations (n=3)
Excluded from analysis because of
protocol violations (n=7)
Analysed (n=20) Analysed (n=20)
Participated in the study
Fig 2 Consort diagram describing the flow of subjects within the study.
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Fig 3 Study protocol graphically showing the order of events during the data acquisition.
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additional samples at ROC and at LOC2. These blood samples
were kept refrigerated until arrival at the laboratory where
they were centrifuged, and the supernatant was removed.
The resulting plasma samples were stored at 2208C. After
thawing, propofol assays were performed atroom temperature
within 24 h as described below. This propofol assay is based
upon an assay for propofol in cerebrospinal fluid as described
by Peeters and colleagues.6
Plasma propofol concentration measurement
Extraction procedure
Fifty microlitres of thymol stock solution (20 mg litre21) were
added to 200 ml of plasma samples. Two hundred microlitres
of water, 400 ml of borate buffer (pH¼9), and 500 ml of
n-heptane were added and mixed thoroughly for 20 min on a
Heidolph Reax 2 mixer (Scientific Ltd, New Brunswick, NJ,
USA). After centrifugation for 5 min at 3000 rpm, the glass
tube was placed at 2408C. The organic layer was then trans-
ferred to an injection vial and 1.0 ml was injected to the
GC-MS system.
Apparatus and chromatographic conditions
A PerkinElmer Autosystem XL GC-MS system (Benelux BV) with
a PerkinElmer automatic sampler and a PerkinElmer Turbo-
mass Gold, Quadrupole detector was used.
Separation was performed by injection in the spitless mode
(valve time 50 s) of 1.0ml of the extract to a Chrompack VF 5ms
MS capillary column (25×0.25 mm ID, film thickness 0.25 mm,
Agilent, art. CP8941). The injector temperature was 2508C and
the oven temperature was held at 808C for 1 min, increased at
108C min21 up to 1608C. The transfer line temperature was set
to 2508C. The helium gas flow rate was 1.5 ml min21. The elec-
tron energywasset at 70 eV. The propofol and thymol ions were
detected by using molecular ions at m/z 178 and 150, respect-
ively, and for the quantitation of the major ions due to loss of
methylgroups at m/z 163 and 135, respectively. Under these
conditions, the retention times of propofol and thymol were
6.54 and 5.71 min, respectively.
Accuracy and precision
The calibration curve was linear (weighing 1/x) in the range
0.25–25 mg litre21. The limit of quantitation was defined as
the concentration where the overall bias and coefficient of vari-
ation (CV) of the accuracy and precision lies within 20% and
proved to be 0.252 mg litre21.
Intra- and inter-day CVs (% CV) were obtained using plasma
samples spiked with four known quality control (QC) concen-
trations of propofol (0.252, 0.804, 10, and 20.1 mg litre21).
For 3 days, the QCwas prepared and analysed in six-fold. Propo-
fol plasma concentration in control samples was stable at tem-
peratures between 4 and 208C for at least 4 days and during
four freeze/thaw cycles. Results are shown in the Appendix.
Tumour volume measurement
Preoperative MRI scans of all tumour patients were uploaded to
a radiotherapy treatment planning system Pinnacle 9.1 &
(Philips). Under the supervision of a dedicated head and neck
radiation oncologist (R.J.H.M.S.), the tumour boundaries were
manually drawn on transverse slices of either T1 (with or
without gadolinium enhancement) or T2 MRI images. Using
these contours, Pinnacle software was then used to calculate
tumour volumes.
Statistical analysis
Our sample size calculation was based on the following para-
meters and assumptions. We chose a of 0.05, b of 0.2, and a
clinically significant difference in the mean BIS value at LOC
and ROC of 10. Based on an assumption that the variability in
BIS at LOC would be similar to that in a previously reported
study [where the standard deviation (SD) was 11 and 20 in
control and tumour patients, respectively],1 we calculated that
two groups of 18 patients needed to be included in the study,
andarbitrarily roundedthisupto20pergroup.Wetestedfornor-
mality the distribution of all samples (LOC1, ROC, and LOC2) for
both groups for all reported variables, using the Shapiro–Wilk
test. We accepted the hypothesis of normal distribution if
P.0.05. Patient characteristic variables were normally distribu-
ted. Differences in patient characteristic variables were tested
for statistical significance with Student’s t-test for continuous
variables and the x2 test for categorical variables. BIS, propofol
concentrations, and haemodynamic variables were generally
all normally distributed at most sampling points. However, for
each variable, the distribution was not normal in one group
(tumour or control group) at at least one sampling point. There-
fore, these variables are summarized as the median [inter-
quartile range (IQR)]. Differences in these values between the
groups were tested for statistical significance with the Mann–
Whitney U-test or Student’s t-test as appropriate.
Results
The CONSORTdiagram summarizing eligibilityand enrolment is
shown in Figure 2. A total of 53 patients consented to enrol-
ment in the study. One consented patient in each group did
not participate in the study because of inadequate staffing
on the day of the procedure. In one patient, the study was ter-
minated soon after the start when unexpected (patient) move-
ment dislodged the arterial cannula. Three patients in the
study group and five patients in the control group were
excluded from further analysis, because they did not show
clear responses to command during induction or recovery,
despite other signs of consciousness (such as purposeful
movement). One further patient was excluded from the ana-
lysis in the control group because of hypotension requiring
administration of vasopressors.
Patientcharacteristicdata and tumourcharacteristics of the
remaining patients are displayed in Tables 1 and 2. The mean
(SD) tumour volume was 59.5 (43.6) cm3. Among the tumour
patients, 10 were receiving anti-epileptic medication and 17
were receiving steroids before operation; among the control
patients, nonewere using anti-epileptic medication or steroids.
There were no significant differences in patient characteristics
between the study and control groups.
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BIS values for all patients before and after each LOC1, ROC,
and LOC2 are shown in Figure 4. The median BIS values recorded
at these transitions did not differ between the groups (Fig. 5),
and were not different between hemispheres in both tumour
and control patients.
Six patients in the study group and five patients in the control
group showed purposeful movements of the unparalysed arm in
response to the noxious stimulus 15 min after LOC1.
LOC1 occurred equally fast in both groups [tumour patients
148 (24) s vs control patients 145 (38) s]. The median (IQR) total
propofol doses at LOC1 were 82 (75–92) and 78 (68–91) mg in
patients with and without brain tumours, respectively. There
were neitherdifferences in estimated and measured plasma pro-
pofol concentrations nor in estimated effect-site concentrations,
at any of the transitions of consciousness (Table 3). ROC occurred
onaverage17.3 (5.5) min after interruption of propofol infusion in
tumour patients and 17.5 (5.3) min in control patients.
Discussion
Frontal brain tumours might reasonably be expected to
contain tissue that is electrically pathologically active or that
is at the very least not interacting normally with adjacent neu-
rones. Thus, the presence of a tumour, orof cerebral oedema, in
the vicinity of an EEG electrode might result in recorded elec-
trical activity that is different from that found on the contralat-
eral side. Likewise, it may also result in recorded activity that
has different morphology, frequency, or phase content for a
given state of consciousness, when compared with other
patients. Since the BIS calculation depends on all of these
factors,7 we used a bilateral BIS recording montage and
monitor to investigate whether the presence of a unilateral
frontal brain tumour has an influence on measured BIS
values recorded at transitions between consciousness and un-
consciousness. In patients with tumours, we found no signifi-
cant differences between BIS values recorded over the
ipsilateral and contralateral hemispheres at these transitions.
Furthermore, there were no significant differences among the
BIS values recorded at the moments of transition of conscious
state among tumour and non-tumour (control) patients.
These findings are consistent with those of Ferreira and col-
leagues1 who reported that even though BIS values were higher
in patients with brain tumours during induction, the BIS values
at the moment of LOC did not significantly differ between both
groups. The development of the BIS algorithm and monitor has
been described in detail.7 In essence, the algorithm monitor
was developed by discriminant analysis of a range of candidate
mathematical and statistical parameters calculated from the
EEG of normal volunteers, to provide an index of the depth of
hypnosis. The BIS is sensitive to some sources of interference
(e.g. signals from the electromyogram can cause false eleva-
tions),8 and can detect some, presumably subtle, changes
such as a change in electrical activity when ketamine is used
as an anaesthetic adjunct.9 However, some studies have
shown the BIS monitor output to be insensitive to significant
changes in raw EEG. In one study, no differences were found
in BIS values measured over the left and right hemisphere in
patients undergoing the Wada test.10 During this test, one hemi-
sphere is rendered functionally inactive by intra-carotid injection
of a short-acting barbiturate. In this study, despite the fact that
the unprocessed EEG showed a significant lateralized cortical
effect, there was no difference between left and right BIS values.
All-in-all, with regard to our patients, two possibilities exist.
The first is that the presence of frontal brain tumours in our
patients did not result in cortical EEG changes. The second pos-
sibility is that changes were induced, but were not detected by
the BIS monitor. To determine which of these was the case,
further studies, for which comprehensive multichannel EEG
recording, would be required.
A secondary aim of our study was to investigate whether
propofol requirements were different in patients with frontal
brain tumours. There are many potential reasons why the
presence of a brain tumour might alter the pharmacodynamics
of a hypnotic agent. These include the presence of local pres-
sure effects on pathways and structures important for con-
sciousness (e.g. brainstem and thalamus), chemical irritation,
inflammation, and the adverse effects of raised intracranial
pressure on cerebral blood flow. Previous work by Chan and
colleagues3 had suggested that propofol doses required to
suppress responses to verbal and tetanic stimuli are lower
in patients with large brain tumours [mean (SD) 69.6 (27.1)
cm3] compared with control patients and patients with
smaller tumours [mean (SD) 5 (4.8) cm3]. We could not
confirm these findings. In our study, tumour and control




Tumour pathology (n) 20
Glioma [n (%)] 8 (40)
Meningioma [n (%)] 8 (40)
Metastasis [n (%)] 4 (20)
Tumour dimensions [mean (SD)]
Anterior/posterior (cm) 5.1 (1.9)
Lateral/medial (cm) 4.1 (1.8)
Coronal/caudal (cm) 4.4 (1.7)
Volume (cm3) 59.5 (43.6)
Midline shift (Y/N) 15/5
Oedema (Y/N) 16/4
Table 1 Patient characteristics. Mean (SD)
Tumour patients Control patients P-value
Age (yr) 50 (14) 56 (10) 0.16
Gender (M/F) 12/8 9/11 0.31
Height (cm) 177 (10) 174 (8) 0.93
Weight (kg) 84 (13) 79 (14) 0.30
ASA (I/II/III) 2/15/3 8/12/0 0.23
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patients showed neither differences in propofol dose required
for LOC nor differences in measured plasma propofol concen-
tration and estimated effect-site concentration at transitions
of consciousness. The reasons for this discrepancy are not
clear, but may be related to factors such as tumour size and
position. The average tumour volume among our patients
was 58 (43) cm3 and thus smaller than the volume of large
tumours in Chan and colleagues’ study.3 Our study was con-
ducted exclusively in patients with frontal brain tumours,
whereas Chan and colleagues3 included patients with cerebral
tumours in a variety of locations.
There are a few limitations of our study. As with most BIS data
sets recorded at transitions of consciousness, the variability in
BIS values is high, especially at the moment of LOC before neuro-
muscular blocking agent administration (Fig. 4). The processing
delay of the BIS monitor varies with the signal quality. During
LOC, the EEG signal quality is often poor since it is contaminated
with signals from the muscles, thereby causing variable process-
ing delays, and greater variability in BIS values.
A second limitation is the unavoidable inherent imprecision
in registration of the moment of LOC or ROC. During transitions
of consciousness, the BIS often changes rapidly. Thus, any
delays in detecting the moment of LOC or ROC will lead to in-
accurate registration of the BIS at the transition and increase
the variability in the data. During the planning of the study,
we sought a balance between precise determination of the
moment of LOC/ROC and alteration of the level of conscious-
ness by patient stimulation. The 10 s interval we chose for as-
sessment of the state of consciousness thus limits the
precision of the data.
Finally, it should be remembered that the BIS was designed
to provide an index or estimate of the hypnotic component of
anaesthesia. While it may be said that the monitor output pro-
vides some idea of the probability of consciousness or recall, it
is not designed to detect the moment of LOC, or to give an ab-
solute indication of the presence or absence of consciousness.
In this way, the monitor output is analogous to that of an arter-
ial pressure monitor, which reports the arterial pressure, but
makes no judgement on the presence or absence of hypoten-
sion, or ischaemia.
In conclusion, BIS values at LOC and ROC are similar in
patients with frontal brain tumours, to those recorded in
control patients. Propofol requirements for LOC were also
similar among tumour and non-tumour patients. The presence
Fig 4 Plots representing individual (thin lines) and average (thick lines) BIS values [(BIS value collected over the left hemisphere+BIS value col-
lected over the right hemisphere)/2] of patients recorded around the time of LOC or ROC for control and tumour patients. Time 0 is the moment
of transition of consciousness. LOC1, the first moment of loss of consciousness. LOC2, the second moment loss of consciousness. ROC, the
moment of return of consciousness.
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of a frontal brain tumour need not influence the placement of
unilateral BIS electrodes, nor the decision whetheror not to use
BIS monitoring for titrating anaesthetic administration.
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Ce, propofol effect-site concentration
Control patients Tumour patients
LOC 1
Cp estimated 14.6 (13.4–15.2) 14 (13.4–14.6)
Cp measured 12.6 (11.5–15.1) 11.5 (9.2–14.4)
Ce estimated 6.4 (5.2–7.8) 6.1 (5.4–6.6)
ROC
Cp estimated 0.9 (0.7–1.2) 0.9 (0.8–1.1)
Cp measured 0.8 (0.6–1.1) 0.7 (0.5–0.8)
Ce estimated 1.1 (0.8–1.4) 1.0 (0.7–1.3)
LOC 2
Cp estimated 12.5 (11.8–14.2) 12.3 (11.1–14.0)
Cp measured 13.4 (11.1–15.4) 10.4 (8.7–13.9)
Ce estimated 4.0 (3.5–5.1) 4.1 (3.3–4.9)
Appendix Stability of propofol samples at different











0.252 8.3 6.9 8.7
0.804 5.1 4.3 8.3 106.7
10 8.4 5.0 3.1
20.1 9.3 4.4 20.5 113.5





















Fig 5 Plots representing individual (thin lines) and median (thick
lines) BIS values [BIS value tumour patients: BIS measured over
hemisphere containing tumour. BIS value control patients: (BIS
left hemisphere+BIS right hemisphere)/2] of patients recorded
around the time of LOC or ROC for control and tumour patients.
LOC1, loss of consciousness 1. ROC, return of consciousness.
LOC2, loss of consciousness 2.
Frontal brain tumour, bilateral BIS, and propofol BJA
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